National Stroke Foundation

Nutropin (somatropin-rDNA origin)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved December 1997

Specific Treatments:

growth hormone deficiency

Therapeutic Areas

General Information

The liquid formulation of Nutropin (somatropin injection) has been approved for the replacement of endogenous growth hormone in adult patients with growth hormone deficiency. The product is currently indicated for pediatric growth hormone deficiency and chronic renal insufficiency.